Forensic Toxicology

, Volume 31, Issue 1, pp 76–85 | Cite as

Analysis of azepane isomers of AM-2233 and AM-1220, and detection of an inhibitor of fatty acid amide hydrolase [3′-(aminocarbonyl)(1,1′-biphenyl)-3-yl]-cyclohexylcarbamate (URB597) obtained as designer drugs in the Tokyo area

  • Jun’ichi Nakajima
  • Misako Takahashi
  • Takako Seto
  • Chieko Kanai
  • Jin Suzuki
  • Masao Yoshida
  • Nozomi Uemura
  • Tomoko Hamano
Original Article

Abstract

During our careful survey of unregulated drugs from November 2011 to January 2012 in the Tokyo area, we found two new compounds in commercial products. The first was identified as the benzoylindole (2-iodophenyl)[1-(1-methylazepan-3-yl)-1H-indol-3-yl]methanone (2), which is the azepane isomer of AM-2233 (1). Compound 2 was isolated by silica gel column chromatography, and was identified through a combination of liquid chromatography–mass spectrometry, gas chromatography–mass spectrometry, accurate mass spectrometry, and nuclear magnetic resonance spectroscopy. The second compound was identified as [3′-(aminocarbonyl)(1,1′-biphenyl)-3-yl]-cyclohexylcarbamate (URB597, 5) by comparing analytical data with that of the authentic compound. For quantitation of these three compounds, each commercial product was extracted with methanol under ultrasonication to prepare the solution for analysis by liquid chromatography with ultraviolet detection. The occurrence of compounds 1 and 2, and AM-1220 (3) and its azepane isomer (4) in 29 commercial products found in the Tokyo area are also shown in this report.

Keywords

Azepane isomers of AM-2233, AM-1220 URB597 Designer drug 

References

  1. 1.
    Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y, Goda Y (2009) Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem Pharm Bull 57:439–441PubMedCrossRefGoogle Scholar
  2. 2.
    Uchiyama N, Kikura-Hanajiri R, Kawahara N, Goda Y (2009) Identification of a cannabimimetic indole as a designer drug in a herbal product. Forensic Toxicol 27:61–66CrossRefGoogle Scholar
  3. 3.
    Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2010) Identification and quantitation of two cannabimimetic phenylacetylindoles JWH-251 and JWH-250, and four cannabimimetic naphthoylindoles JWH-081, JWH-015, JWH-200, and JWH-073 as designer drugs in illegal products. Forensic Toxicol 29:25–37CrossRefGoogle Scholar
  4. 4.
    Nakajima J, Takahashi M, Seto T, Suzuki J (2011) Identification and quantitation of cannabimimetic compound JWH-250 as an adulterant in products obtained via the Internet. Forensic Toxicol 29:51–55CrossRefGoogle Scholar
  5. 5.
    Nakajima J, Takahashi M, Seto T, Kanai C, Suzuki J, Yoshida M, Hamano T (2011) Identification and quantitation of two benzoylindoles AM-694 and (4-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone, and three cannabimimetic naphthoylindoles JWH-210, JWH-122, and JWH-019 as adulterants in illegal products obtained via the Internet. Forensic Toxicol 29:95–110CrossRefGoogle Scholar
  6. 6.
    Nakajima J, Takahashi M, Nonaka R, Seto T, Suzuki J, Yoshida M, Kanai C, Hamano T (2011) Identification and quantitation of a benzoylindole (2-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone and a naphthoylindole 1-(5-fluoropentyl-1H-indol-3-yl)-(naphthalene-1-yl)methanone (AM-2201) found in illegal products obtained via the Internet and their cannabimimetic effects evaluated by in vitro [35S]GTPγS binding assays. Forensic Toxicol 29:132–141CrossRefGoogle Scholar
  7. 7.
    Nakajima J, Takahashi M, Seto T, Yoshida M, Kanai C, Suzuki J, Hamano T (2012) Identification and quantitation of two new naphthoylindole drugs-of-abuse, (1-(5-hydroxypentyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone (AM-2202) and (1-(4-pentenyl)-1H-indol-3-yl)(naphthalen-1-yl)methanone, with other synthetic cannabinoids in unregulated “herbal” products circulated in the Tokyo area. Forensic Toxicol 30:33–44CrossRefGoogle Scholar
  8. 8.
    Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2012) Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide (APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233. AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products. Forensic Toxicol 30:114–125CrossRefGoogle Scholar
  9. 9.
    Aichi Prefecture (2012) http://www.pref.aichi.jp/0000048628.html. Accessed Aug 2012
  10. 10.
    Health and Social Welfare Bureau, Yokohama City (2012) http://www.city.yokohama.lg.jp/kenko/imuyakumu-jyouhou/20120524154212.html. Accessed Aug 2012
  11. 11.
    Kneisel S, Bisel P, Brecht V, Broecker S, Müller M, Auwarter V (2012) Identification of the cannabimimetic AM-1220 and its azepane isomer (N-methylazepan-3-yl)-3-(1-naphthoyl)indole in a research chemical and several herbal mixtures. Forensic Toxicol 30:126–134CrossRefGoogle Scholar
  12. 12.
    Ministry of Health, Labour and Welfare of Japan (2012) http://www.mhlw.go.jp/bunya/iyakuhin/yakubuturanyou/kanren-tuchi/yakuji/dl/H24-01.pdf. Accessed 8 Aug 2012
  13. 13.
    Piomelli D, Tarzia G, Duranti A, Tontini A, Mor M, Compton TR, Dasse O, Monaghan EP, Parrott JA, Putman D (2006) Pharmacological profile of the selective FAAH inhibitor KDS-4103 (URB597). CNS Drug Rev 12(1):21–38PubMedCrossRefGoogle Scholar
  14. 14.
    Clapper JR, Mangieri RA, Piomelli D (2009) The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology 56:235–243PubMedCrossRefGoogle Scholar

Copyright information

© Japanese Association of Forensic Toxicology and Springer Japan 2012

Authors and Affiliations

  • Jun’ichi Nakajima
    • 1
  • Misako Takahashi
    • 1
  • Takako Seto
    • 1
  • Chieko Kanai
    • 1
  • Jin Suzuki
    • 1
  • Masao Yoshida
    • 1
  • Nozomi Uemura
    • 1
  • Tomoko Hamano
    • 1
  1. 1.Division of DrugsTokyo Metropolitan Institute of Public HealthTokyoJapan

Personalised recommendations